Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Brève: Premier traitement du MERS en essai clinique</title>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmc">7140275</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140275</idno>
<idno type="RBID">PMC:7140275</idno>
<idno type="doi">10.1016/S1773-035X(16)30316-1</idno>
<idno type="pmid">NONE</idno>
<date when="2016">2016</date>
<idno type="wicri:Area/Pmc/Corpus">000649</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000649</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Brève: Premier traitement du MERS en essai clinique</title>
</analytic>
<series><title level="j">Revue Francophone Des Laboratoires</title>
<idno type="ISSN">1773-035X</idno>
<idno type="eISSN">1773-0368</idno>
<imprint><date when="2016">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<back><div1 type="bibliography"><listBibl><biblStruct></biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<pmc article-type="brief-report" xml:lang="fr"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Rev Francoph Lab</journal-id>
<journal-id journal-id-type="iso-abbrev">Rev Francoph Lab</journal-id>
<journal-title-group><journal-title>Revue Francophone Des Laboratoires</journal-title>
</journal-title-group>
<issn pub-type="ppub">1773-035X</issn>
<issn pub-type="epub">1773-0368</issn>
<publisher><publisher-name>Elsevier Masson SAS.</publisher-name>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="pmc">7140275</article-id>
<article-id pub-id-type="publisher-id">S1773-035X(16)30316-1</article-id>
<article-id pub-id-type="doi">10.1016/S1773-035X(16)30316-1</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Article</subject>
</subj-group>
</article-categories>
<title-group><article-title>Brève: Premier traitement du MERS en essai clinique</article-title>
</title-group>
<pub-date pub-type="pmc-release"><day>9</day>
<month>11</month>
<year>2016</year>
</pub-date>
<pmc-comment> PMC Release delay is 0 months and 0 days and was based on .</pmc-comment>
<pub-date pub-type="ppub"><month>11</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub"><day>9</day>
<month>11</month>
<year>2016</year>
</pub-date>
<volume>2016</volume>
<issue>486</issue>
<fpage>18</fpage>
<lpage>18</lpage>
<permissions><copyright-statement>Copyright © 2016 Elsevier Masson SAS. All rights reserved.</copyright-statement>
<copyright-year>2016</copyright-year>
<copyright-holder>Elsevier Masson SAS</copyright-holder>
<license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p>
</license>
</permissions>
</article-meta>
</front>
<body><p id="par0005"><fig id="fig0005"><caption><p>© Onidji/Fotolia.com</p>
</caption>
<graphic xlink:href="gr1"></graphic>
</fig>
</p>
<p id="par1005">Aux USA, les NIH évaluent un traitement-candidat du MERS-CoV (<italic>Middle East Respiratory Syndrome-Coronavirus</italic>
), ou syndrome respiratoire du Moyen-Orient à Coronavirus, proposé par la biopharma SAB Biotherapeutics. Cet essai de phase 1 est conduit par les NIH pour évaluer le dosage et la sécurité de ce traitement, à base d’anticorps humains, ou SAB-301. Le MERS-CoV est une maladie respiratoire récemment découverte, il n’existe encore ni vaccin ni traitement. SAB Therapeutics produit le SAB-301 sur sa plateforme DiversitAb<sup>®</sup>
, à partir de bétail génétiquement modifié (Tc Bovine<sup>®</sup>
) pour produire de grandes quantités d’anticorps polyclonaux humains (immunoglobuline G) en réponse à l’administration de l’antigène viral du MERS. Les bovins produisent rapidement d’importantes quantités d’anticorps humains, recueillis dans le plasma et purifiés Selon SAB, la plateforme DiversitAb<sup>®</sup>
est la première à partir de laquelle des anticorps entièrement humains ont été produits sur de grands animaux. Les premiers résultats devraient être publiés début 2017</p>
</body>
<back><ref-list id="fur0005"><title>Source</title>
<ref id="bib1010"><mixed-citation publication-type="other" id="oref0005"><ext-link ext-link-type="uri" xlink:href="http://www.sabbiotherapeutics.com/" id="intr0005">www.sabbiotherapeutics.com</ext-link>
</mixed-citation>
</ref>
</ref-list>
</back>
</pmc>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000649 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000649 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= MersV1 |flux= Pmc |étape= Corpus |type= RBID |clé= |texte= }}
![]() | This area was generated with Dilib version V0.6.33. | ![]() |